Bones no, tendons and ligaments yes.
I'm not sure if we'll miss bones as a opportunity. The net net rev potential on the colon tool, with what we've been told and can figure out on our own, should have a potential
1-200 million $. We won't get all of it, or at once, but a subdivision goal of 25% of this market over 2 years(>< 40 million net net before) seems doable to me as there's no like RF competators and the Surgeons already use a like tool(stapler).
Upside to the equation would be the increase in this procedure
due to aging populace, larger numbers of decisions to do the procedure due to less risk and more comfort for patient.
A upside that will gradualy become effective and in a major way, moreso than anything else, will be the additional LTC tools that will be used in this or any other individual procedure, as they come on line.
Anyway, 40 mill @ 20x could put a smile on your face. For that one subdivision, I mean.
With luck, we will be in FDA by years end for that tool.